- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
Patent holdings for IPC class A61P 25/14
Total number of patents in this class: 1642
10-year publication summary
46
|
68
|
80
|
125
|
158
|
149
|
136
|
163
|
123
|
38
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Takeda Pharmaceutical Company Limited | 2961 |
34 |
Taisho Pharmaceutical Co., Ltd. | 844 |
32 |
Neurocrine Biosciences, Inc. | 381 |
25 |
Auspex Pharmaceuticals, Inc. | 205 |
23 |
Daiichi Sankyo Company, Limited | 1829 |
19 |
Kyoto University | 2732 |
16 |
Sage Therapeutics, Inc. | 312 |
15 |
PTC Therapeutics, Inc. | 492 |
14 |
The Regents of the University of California | 18943 |
13 |
Banyu Pharmaceutical Co., Ltd. | 107 |
13 |
Ovid Therapeutics Inc | 151 |
13 |
Sumitomo Dainippon Pharma Co., Ltd. | 226 |
13 |
Adeptio Pharmaceuticals Limited | 21 |
13 |
Prilenia Neurotherapeutics Ltd. | 83 |
13 |
F. Hoffmann-La Roche AG | 7958 |
12 |
Shionogi & Co., Ltd. | 914 |
12 |
Tohoku University | 2526 |
11 |
Vanderbilt University | 1731 |
11 |
Allergan, Inc. | 2600 |
10 |
Sunshine Lake Pharma Co., Ltd. | 542 |
10 |
Other owners | 1320 |